3/1/2011

Shire obtained FDA approval for extended-release Intuniv as an add-on treatment to stimulants
for attention-deficit/hyperactivity disorder in 6- to 17-year-olds. Intuniv is already used as monotherapy for this patient group.

Related Summaries